Antioxidant Compounds as Allies of Nutritional Treatment in Adiposity-Based Chronic Disease

Currently, 1 in 3 people have an adiposity-based chronic disease (ABCD), a situation that in recent decades has been on the rise. The systemic oxidative stress characteristic of ABCD is a complex and systemic state that derives from the deregulation of the musculoskeletal system and the loss of cellular antioxidant capacity. In the present review, we analyze the mechanisms of antioxidant bioactive compounds that, in clinical evidence, have shown a potential effect on the reduction of oxidative stress in people with ABCD. Research presented in this review was identified through searches of PubMed/Medline, EMBASE and the Cochrane Library databases. Observational studies report that people with ABCD have lower serum concentrations of antioxidants such as vitamins C, E and coenzyme Q10. Scientific evidence affirms that the use of antioxidants in the nutritional therapy of people with ABCD results in a decrease in prooxidative markers. In clinical practice, various factors such as diet, pharmacotherapy, stress levels and disease progression could reduce the efficacy of antioxidant compounds in the nutritional treatment of ABCD. The appropriate dosage of bioactive compounds with antioxidant effects results in a potential ally in the metabolic control of people with ABCD.